VLDL receptor gene therapy for reducing atherogenic lipoproteins
Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low-density lipoprotein cholesterol (LDL-C), there is...
Saved in:
Main Authors: | Ronald M. Krauss (Author), Jonathan T. Lu (Author), Joseph J. Higgins (Author), Cathryn M. Clary (Author), Ray Tabibiazar (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progression of Chronic Kidney Disease Affects HDL Impact on Lipoprotein Lipase (LPL)-Mediated VLDL Lipolysis Efficiency
by: Agnieska Ćwiklińska, et al.
Published: (2018) -
OBICETRAPIB TARGETS ALL ATHEROGENIC LIPOPROTEINS BEYOND LDL-C
by: Michael Davidson, MD
Published: (2024) -
Atherogenic Index and High-Density Lipoprotein Cholesterol as Cardiovascular Risk Determinants in Rheumatoid Arthritis: The Impact of Therapy with Biologicals
by: Calin D. Popa, et al.
Published: (2012) -
GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance
by: Jennifer Taher, et al.
Published: (2014) -
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease
by: Mohammad Zarei, et al.
Published: (2018)